StockData
Adastra Holdings Ltd. logo

Adastra Holdings Ltd. (XTXXF) stock

XTXXFOTCPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2022, năm kết thúc ngày Dec 31, 2022Last filing: 20-F on May 17, 2023
$0.01+0.00 (0.00%)

Close on Oct 19, 2026

Adastra Holdings Ltd. grew revenue 136.2% to C$13.30M over fiscal 2022. Free cash flow was C$694.07K.

Revenue
C$13.30M
+136.2% vs. a year earlier
Operating income
-C$800.00K
FY2022
Free cash flow
C$694.07K
FY2022
EPS, diluted
-0.07 CAD
FY2022

Key statistics

Valuation at the latest close; fundamentals over fiscal 2022, balances at Dec 31, 2022

Valuation

Market cap
–
P/E ratio
–
Price to sales
–
Price to book
–
Dividend yield
–
Free cash flow yield
–

Fundamentals

Revenue
C$13.30M
EPS, diluted
-0.07 CAD
Free cash flow
C$694.07K

Trading

Previous close
$0.01
Open
$0.01
Day's range
$0.01 – $0.01
Volume
0

Valuation needs the share price. It fills in once daily prices are connected and converted from CAD.

Market cap history

Month-end market cap since 2021, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.

PeriodXTXXFS&P 500DifferenceXTXXF per yearS&P 500 per year
1 month0.0%+0.6%−0.6 pts
3 months0.0%+3.4%−3.4 pts
Year to date-30.0%+13.3%−43.3 pts
1 year-98.6%+16.6%−115.2 pts
3 years-99.4%+86.4%−185.8 pts-81.6%+23.1%
5 years-99.9%+81.9%−181.8 pts-76.2%+12.7%

Three years at a glance

Fiscal years 2020 to 2022, CAD

Revenue

C$13.30M+136.2% YoY

Gross profit

C$6.11M+214.5% YoY

Operating income

-C$800.00K

EPS, diluted

-0.07 CAD

Free cash flow

C$694.07K
Reported period

Press releases

Releases Adastra filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Adastra

Pharmaceutical Preparations

Adastra Holdings Ltd. is an extraction and processing solutions company operating in the Canadian cannabis sector. It develops and utilizes extraction technologies, including supercritical carbon dioxide, cryogenic ethanol, and hydrocarbon systems, to process cannabis and hemp biomass into bulk distillates, oils, hydrocarbon extracts, shatter, and vaporizing products. Through its Chemia Analytics subsidiary, the company conducts analytical and organoleptic testing services, covering potency, microbial contamination, and formulation consulting. Its PerceiveMD clinic operations involve healthcare professionals providing medical cannabis consultations and therapies. Adastra serves licensed cannabis standard cultivators, micro-cultivators, processors, provincial distributors, and medical patients.

Company profile, executives and history

Adastra stock: common questions

What is Adastra's stock price?

XTXXF closed at $0.01 on Oct 19, 2026, up 0.00% on the day.

What is XTXXF's P/E ratio?

Adastra lost money over fiscal 2022 (diluted EPS -0.07 CAD), so it has no meaningful P/E ratio.

How much revenue does Adastra make?

Adastra reported revenue of C$13.30M for fiscal 2022, up 136.2% from a year earlier.

Does Adastra pay a dividend?

No. Adastra has not paid a cash dividend over the last twelve months.

How has XTXXF stock performed over the past year?

Including dividends, XTXXF returned -98.6% over the past year, against +16.6% for the S&P 500.

Who are Adastra's competitors?

Companies most similar to Adastra by business, industry and size include OGI, CPMD, INCR, BHST, VREOF.

See a number that looks wrong?